| __timestamp | Neurocrine Biosciences, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 520990000000 |
| Thursday, January 1, 2015 | 33800000 | 535405000000 |
| Friday, January 1, 2016 | 35900000 | 558755000000 |
| Sunday, January 1, 2017 | 1254000 | 495921000000 |
| Monday, January 1, 2018 | 4889000 | 659690000000 |
| Tuesday, January 1, 2019 | 7400000 | 1089764000000 |
| Wednesday, January 1, 2020 | 10100000 | 994308000000 |
| Friday, January 1, 2021 | 14300000 | 1106846000000 |
| Saturday, January 1, 2022 | 23200000 | 1244072000000 |
| Sunday, January 1, 2023 | 39700000 | 1431505000000 |
| Monday, January 1, 2024 | 34000000 | 1431505000000 |
Data in motion
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. over the past decade. From 2014 to 2023, Takeda's cost of revenue has shown a steady increase, peaking at approximately 1.43 trillion in 2023, reflecting a 174% rise from 2014. In contrast, Neurocrine's cost of revenue, while significantly lower, has experienced a dramatic increase of over 175% during the same period, reaching nearly 40 million in 2023.
This stark contrast highlights the scale and operational differences between the two companies. While Takeda operates on a much larger scale, Neurocrine's rapid growth in cost of revenue suggests an aggressive expansion strategy. Understanding these trends provides valuable insights into the strategic priorities and market positioning of these pharmaceutical giants.
Cost of Revenue Comparison: Pfizer Inc. vs Takeda Pharmaceutical Company Limited
Cost Insights: Breaking Down GSK plc and Neurocrine Biosciences, Inc.'s Expenses
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Exelixis, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated
Neurocrine Biosciences, Inc. vs Walgreens Boots Alliance, Inc.: Efficiency in Cost of Revenue Explored
Neurocrine Biosciences, Inc. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Alkermes plc
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored